Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing targeted therapies. The company's mission is to leverage its proprietary extended-release delivery system to provide optimal drug delivery for therapeutic areas with high unmet medical needs. Eupraxia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.

At the core of Eupraxia's innovation is its proprietary Diffusphere™ technology, a polymer-based micro-sphere platform designed for localized, controlled, and extended drug delivery. The company's pipeline includes two primary clinical development programs: EP-104GI, which is in a Phase 1b/2a trial (RESOLVE trial) for the treatment of eosinophilic esophagitis (EoE), and EP-104IAR, which has completed a Phase 2b clinical trial (SPRINGBOARD) for chronic osteoarthritis pain in the knee.

In recent news, Eupraxia Pharmaceuticals announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer on May 1, 2026, succeeding Dr. Mark Kowalski. The company also reported positive 36-week data from its Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis, demonstrating significant improvements in symptom response and tissue health. Furthermore, Eupraxia completed a public offering in February 2026, raising approximately US$63.2 million to advance its clinical development programs and for general corporate purposes.